The Secondary Acute Myeloid Leukemia drugs in development market research report provides comprehensive information on the therapeutics under development for Secondary Acute Myeloid Leukemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Secondary Acute Myeloid Leukemia. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Secondary Acute Myeloid Leukemia and features dormant and discontinued products.
GlobalData tracks ten drugs in development for Secondary Acute Myeloid Leukemia by nine companies/universities/institutes. The top development phase for Secondary Acute Myeloid Leukemia is phase ii with four drugs in that stage. The Secondary Acute Myeloid Leukemia pipeline has nine drugs in development by companies and one by universities/ institutes. Some of the companies in the Secondary Acute Myeloid Leukemia pipeline products market are: Novartis, Xuzhou Medical University and Celularity.
The key targets in the Secondary Acute Myeloid Leukemia pipeline products market include Cells Expressing Interleukin 3 Receptor Subunit Alpha (CD123 or IL3RA), Cells Expressing Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2), and CD3 .
The key mechanisms of action in the Secondary Acute Myeloid Leukemia pipeline product include Cytotoxic To Cells Expressing Interleukin 3 Receptor Subunit Alpha (CD123 or IL3RA) with two drugs in Phase II. The Secondary Acute Myeloid Leukemia pipeline products include four routes of administration with the top ROA being Oral and four key molecule types in the Secondary Acute Myeloid Leukemia pipeline products market including Small Molecule, and Gene-Modified Cell Therapy.
Secondary Acute Myeloid Leukemia overview
Secondary acute myeloid leukemia includes acute myeloid leukemia that arises either from a previous myeloid hematologic disease such as myelodysplastic syndrome, chronic myeloproliferative syndrome, or myelodysplastic/myeloproliferative overlap syndromes or from a previous chemotherapy or radiotherapy performed for another disease
For a complete picture of Secondary Acute Myeloid Leukemia’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
